Submit Manuscript

International Journal of Osteoporosis and Metabolic Disorders

Year: 2011 | Volume: 4 | Issue: 1 | Page No.: 1-14
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend

Total views 710

Search

Authors

A.S. Nazrun

M. Norazlina

M. Norliza

S. Ima Nirwana

Keywords

Review Article

Tocotrienols as an Anti-Osteoporotic Agent: The Progress So Far

A.S. Nazrun, M. Norazlina, M. Norliza and S. Ima Nirwana
Osteoporosis is a metabolic bone disease affecting both men and women especially postmenopausal women. Osteoporosis has been associated with oxidative stress and therefore the protective effects of antioxidants such as vitamin E were studied. Lately, there has been a growing interest in tocotrienol, a potent vitamin E with anti-cholesterol, anti-cancer and perhaps anti-osteoporotic properties. We have conducted studies on the effects of tocotrienol on various animal models of osteoporosis and discovered its ability to prevent osteoporosis. In most of the studies, tocotrienol mixtures as well as its isomers such as gamma-, alpha- or delta-tocotrienol were compared to alpha tocopherol, the most abundant and widely commercialized vitamin E. The techniques that were used included Enzyme-linked immunosorbent assay (ELISA), bone histomorphometry, Dual energy X-ray absorptiometry (DEXA) and biomechanical testing. Most of the results revealed that tocotrienols were more efficacious than alpha-tocopherol in protecting the bone from various inducers of osteoporosis. These convincing results warrant further studies in pursuing the idea that in future, tocotrienol would be accepted as part of the treatment regime for osteoporosis. The role of tocotrienols in studies using various osteoporotic models was discussed in light of its potential as an anti-osteoporotic agent.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *